The United States Food and Drug Administration (FDA) has granted orphan drug status to Reata Pharmaceuticals, Inc. for their agent RTA 402 in the treatment of pancreatic cancer.
RTA 402 is an antioxidant inflammation modulator (AIM) that reduces inflammation and oxidative stress.
RTA 402 is currently in a Phase I/II clinical trial.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.